| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 835- | Gra, | Annona muricata leaves induced apoptosis in A549 cells through mitochondrial-mediated pathway and involvement of NF-κB |
| - | in-vitro, | Lung, | A549 |
| 857- | Gra, | The Value of Caspase-3 after the Application of Annona muricata Leaf Extract in COLO-205 Colorectal Cancer Cell Line |
| - | in-vitro, | CRC, | COLO205 |
| 851- | Gra, | Antiproliferation Activity and Apoptotic Mechanism of Soursop (Annona muricata L.) Leaves Extract and Fractions on MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | CV1 |
| 850- | Gra, | Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin |
| - | in-vitro, | PC, | PC3 | - | in-vitro, | Pca, | DU145 |
| 848- | Gra, | AgNPs, | Synthesis, Characterization and Evaluation of Antioxidant and Cytotoxic Potential of Annona muricata Root Extract-derived Biogenic Silver Nanoparticles |
| - | in-vitro, | CRC, | HCT116 |
| 1234- | Gra, | Graviola attenuates DMBA-induced breast cancer possibly through augmenting apoptosis and antioxidant pathway and downregulating estrogen receptors |
| - | in-vivo, | BC, | NA |
| 4236- | H2, | Neuroprotective effects of hydrogen inhalation in an experimental rat intracerebral hemorrhage model |
| - | in-vivo, | Stroke, | NA |
| 1637- | HCA, | OLST, | Orlistat and Hydroxycitrate Ameliorate Colon Cancer in Rats: The Impact of Inflammatory Mediators |
| - | in-vivo, | Colon, | NA |
| 1629- | HCA, | Tam, | Hydroxycitric acid reverses tamoxifen resistance through inhibition of ATP citrate lyase |
| - | in-vitro, | BC, | MCF-7 |
| 1657- | HCAs, | Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29 Human Colon Cancer Cell Line 2023 |
| - | in-vitro, | CRC, | HT-29 |
| 1641- | HCAs, | Lung cancer induced by Benzo(A)Pyrene: ChemoProtective effect of sinapic acid in swiss albino mice |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA |
| 1644- | HCAs, | PBG, | Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis |
| - | in-vitro, | Pca, | LNCaP |
| 1286- | HNK, | The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells |
| - | in-vitro, | CLL, | NA |
| 1153- | HNK, | Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 2073- | HNK, | Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo |
| - | in-vitro, | OS, | U2OS | - | in-vivo, | NA, | NA |
| 4238- | HNK, | Neuropharmacological potential of honokiol and its derivatives from Chinese herb Magnolia species: understandings from therapeutic viewpoint |
| - | Review, | AD, | NA | - | NA, | Park, | NA |
| 4659- | HNK, | Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/β-Catenin Signaling and Apoptosis Induction |
| - | in-vitro, | Oral, | NA |
| 2879- | HNK, | Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function |
| - | in-vitro, | Lung, | H226 | - | in-vivo, | NA, | NA |
| 2881- | HNK, | Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis |
| - | in-vitro, | PC, | PANC1 |
| 2883- | HNK, | Honokiol targets mitochondria to halt cancer progression and metastasis |
| - | Review, | Var, | NA |
| 2868- | HNK, | Honokiol: A review of its pharmacological potential and therapeutic insights |
| - | Review, | Var, | NA | - | Review, | Sepsis, | NA |
| 2867- | HNK, | Honokiol ameliorates oxidative stress-induced DNA damage and apoptosis of c2c12 myoblasts by ROS generation and mitochondrial pathway |
| - | in-vitro, | Nor, | C2C12 |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2885- | HNK, | Honokiol: a novel natural agent for cancer prevention and therapy |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5052- | HPT, | Hyperthermia Induces Apoptosis through Endoplasmic Reticulum and Reactive Oxygen Species in Human Osteosarcoma Cells |
| - | in-vitro, | OS, | U2OS |
| 4640- | HT, | The anti-cancer potential of hydroxytyrosol |
| - | Review, | Var, | NA |
| 4212- | Hup, | Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent PI3K/Akt/mTOR Signaling Pathway |
| - | in-vitro, | Nor, | HT22 |
| 4209- | Hup, | Huperzine A, reduces brain iron overload and alleviates cognitive deficit in mice exposed to chronic intermittent hypoxia |
| - | in-vivo, | NA, | NA |
| 2177- | itraC, | Itraconazole improves survival outcomes in patients with colon cancer by inducing autophagic cell death and inhibiting transketolase expression |
| - | Study, | Colon, | NA | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 1918- | JG, | ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | NA, | NA |
| 1927- | JG, | Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway |
| - | in-vitro, | GC, | SGC-7901 |
| 1926- | JG, | Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway |
| - | in-vitro, | BC, | MCF-7 |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 5113- | JG, | Juglone in Oxidative Stress and Cell Signaling |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5114- | JG, | Juglone, from Juglans mandshruica Maxim, inhibits growth and induces apoptosis in human leukemia cell HL-60 through a reactive oxygen species-dependent mechanism |
| - | in-vitro, | AML, | HL-60 |
| 5115- | JG, | Natural Products to Fight Cancer: A Focus on Juglans regia |
| - | Review, | Var, | NA |
| 866- | Lae, | Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review |
| - | Review, | NA, | NA |
| 860- | Lae, | Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery |
| - | Review, | NA, | NA |
| 862- | Lae, | Molecular mechanism of amygdalin action in vitro: review of the latest research |
| - | Review, | NA, | NA |
| 2351- | lamb, | Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 1064- | LT, | Cisplatin, | Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells |
| - | vitro+vivo, | Lung, | LNM35 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 4292- | LT, | Luteolin for neurodegenerative diseases: a review |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | MS, | NA | - | Review, | Stroke, | NA |
| 2923- | LT, | Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells |
| - | in-vitro, | NA, | NA |
| 2907- | LT, | Protective effect of luteolin against oxidative stress‑mediated cell injury via enhancing antioxidant systems |
| - | in-vitro, | Nor, | NA |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 2915- | LT, | Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | CRC, | SNU-407 | - | in-vitro, | Nor, | FHC |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid